Clinical trial
Cilengitide in Treating Patients With Metastatic Prostate Cancer
NCT00103337 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00103337 |
|---|---|
| Title | Cilengitide in Treating Patients With Metastatic Prostate Cancer |
| Official title | Phase II Evaluation of EMD121974 (NSC 707544, Cilengitide) in Asymptomatic Patients With Metastatic Androgen Independent Prostate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Prostate Cancer, Stage IV Prostate Cancer |
| Intervention type | Drug, Other |
| Interventions | cilengitide, laboratory biomarker analysis |
| Enrollment | 106 |
| Start date | Jan 1, 2005 |
| Primary completion | Oct 1, 2007 |
| First posted | Feb 8, 2005 |
| Last update posted | Feb 28, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: